Literature DB >> 33642170

ECPella: Concept, Physiology and Clinical Applications.

P Meani1, R Lorusso2, F Pappalardo3.   

Abstract

Addition of Impella on top of venoarterial extracorporeal membrane oxygenation (VA-ECMO) has gained wide interest as it might portend improved outcomes in patients with cardiogenic shock. This has been consistently reported in retrospective propensity-matched studies, case series, and meta-analyses. The pathophysiologic background is based on the mitigation of ECMO-related side effects and the additive benefit of myocardial unloading. In this perspective, thorough knowledge of these mechanisms is required to optimize the management of mechanical circulatory support with this approach and introduce best practices, as the interplay between the two devices and the implantation-explantation strategies are key for success.
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  VA ECLS; cardiogenic shock; ecpella; impella; physiology

Mesh:

Year:  2021        PMID: 33642170     DOI: 10.1053/j.jvca.2021.01.056

Source DB:  PubMed          Journal:  J Cardiothorac Vasc Anesth        ISSN: 1053-0770            Impact factor:   2.628


  2 in total

Review 1.  Impella support as a bridge to heart surgery in patients with cardiogenic shock.

Authors:  Shunsuke Saito; Ikuko Shibasaki; Taiki Matsuoka; Ken Niitsuma; Shotaro Hirota; Yasuyuki Kanno; Yuta Kanazawa; Masahiro Tezuka; Yusuke Takei; Go Tsuchiya; Taisuke Konishi; Koji Ogata; Hirotsugu Fukuda
Journal:  Interact Cardiovasc Thorac Surg       Date:  2022-07-09

2.  Impact of extracorporeal CPR with transcatheter heart pump support (ECPELLA) on improvement of short-term survival and neurological outcome in patients with refractory cardiac arrest - A single-site retrospective cohort study.

Authors:  Takashi Unoki; Motoko Kamentani; Tomoko Nakayama; Yudai Tamura; Yutaka Konami; Hiroto Suzuyama; Masayuki Inoue; Megumi Yamamuro; Eiji Taguchi; Tadashi Sawamura; Koichi Nakao; Tomohiro Sakamoto
Journal:  Resusc Plus       Date:  2022-05-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.